Medtronic plc
As of Fiscal Year 2026 (ended April 24, 2026)
Key KPIs at a Glance
| Metric | Value |
|---|---|
| Total revenue (FY2026) | $36.36 billion, up 8.4% year-over-year (5.8% organic) |
| Net income, GAAP (FY2026) | $4.80 billion |
| GAAP diluted EPS (FY2026) | $3.73 |
| Non-GAAP diluted EPS (FY2026) | $5.53 |
| R&D spending (FY2026) | $2.87 billion (7.9% of net sales) |
| Free cash flow (FY2026) | $5.43 billion |
| Cardiovascular segment revenue (FY2026) | $13.98 billion, +9.3% organic growth |
| Neuroscience segment revenue (FY2026) | $10.29 billion, +3.1% organic growth |
| Medical Surgical segment revenue (FY2026) | $8.82 billion, +2.9% organic growth |
| Diabetes segment revenue (FY2026) | $3.11 billion, +7.9% organic growth |
| Employees | 95,000+ employees across more than 150 countries |
| Diabetes business separation status | MiniMed Group, Inc. (former Diabetes segment) completed its IPO in March 2026, with Medtronic retaining ~90% ownership. On Sept 14, 2026, Medtronic launched an exchange offer (expiring Oct 9, 2026, absent extension) letting Medtronic shareholders swap MDT shares for MiniMed shares at a 7% discount, targeting Medtronic's stake below 20%; if under-subscribed, Medtronic intends a follow-on spin-off, split-off, and/or debt-for-equity exchange to complete the separation. |
Sources: All figures are Medtronic-disclosed (company primary sources) unless noted. FY2026 segment and total revenue, net income, EPS, R&D spend, free cash flow and employee count are from Medtronic's 'Reports fourth quarter and full year fiscal 2026 results' press release and SEC Exhibit 99.1 (filed June 3, 2026). Prior-year total revenue figures (FY2022-FY2025) are from Medtronic's respective full-year earnings press releases. Diabetes/MiniMed separation status is from Medtronic's press release dated September 14, 2026 announcing the exchange offer. Segment operating profit is not included because Medtronic does not disclose a clean, comparable segment operating profit breakdown in these releases; only segment revenue is shown. The four disclosed segment revenues for FY2026 sum to $36.19B versus total reported revenue of $36.364B (a ~$0.17B / 0.5% gap), likely reflecting minor reconciling/rounding items across quarters; this gap is not allocated to a segment and is noted in the pie widget's subtitle rather than fabricated as an 'Other' slice.